Anavex Life Sciences Reports听Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Anavex Life Sciences (NASDAQ:AVXL) reported its fiscal 2025 Q3 financial results and provided updates on its clinical developments. The company's lead drug candidate blarcamesine demonstrated continued clinical benefits for early-stage Alzheimer's patients over a 4-year period, as presented at AAIC 2025.
Financial highlights include cash position of $101.2 million as of June 30, 2025, providing over 3 years of runway. Q3 net loss was $13.2 million ($0.16 per share), compared to $12.2 million ($0.14 per share) in Q3 2024. R&D expenses decreased to $10.0 million from $11.8 million year-over-year, while G&A expenses increased to $4.5 million from $2.8 million.
Anavex Life Sciences (NASDAQ:AVXL) ha reso noti i risultati finanziari del terzo trimestre dell'esercizio 2025 e ha fornito aggiornamenti sui suoi sviluppi clinici. Il candidato principale, blarcamesine, ha mostrato benefici clinici persistenti nei pazienti con Alzheimer in fase iniziale su un periodo di 4 anni, come presentato all'AAIC 2025.
I punti finanziari rilevanti includono una posizione di cassa pari a $101.2 milioni al 30 giugno 2025, che assicura oltre 3 anni di autonomia finanziaria. La perdita netta del terzo trimestre 猫 stata di $13.2 milioni ($0.16 per azione), rispetto a $12.2 milioni ($0.14 per azione) nel Q3 2024. Le spese per R&S sono diminuite a $10.0 milioni da $11.8 milioni su base annua, mentre le spese G&A sono salite a $4.5 milioni da $2.8 milioni.
Anavex Life Sciences (NASDAQ:AVXL) inform贸 sus resultados financieros del tercer trimestre del ejercicio 2025 y proporcion贸 actualizaciones sobre sus desarrollos cl铆nicos. El candidato principal, blarcamesine, demostr贸 beneficios cl铆nicos continuos en pacientes con Alzheimer en estadio temprano durante un per铆odo de 4 a帽os, seg煤n se present贸 en el AAIC 2025.
Entre los aspectos financieros destaca una posici贸n de caja de $101.2 millones al 30 de junio de 2025, que ofrece m谩s de 3 a帽os de visibilidad financiera. La p茅rdida neta del tercer trimestre fue de $13.2 millones ($0.16 por acci贸n), frente a $12.2 millones ($0.14 por acci贸n) en el Q3 de 2024. Los gastos de I+D se redujeron a $10.0 millones desde $11.8 millones interanual, mientras que los gastos G&A aumentaron a $4.5 millones desde $2.8 millones.
Anavex Life Sciences (NASDAQ:AVXL)電� 2025 須岅硠鞐半弰 3攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頃橁碃 鞛勳儊 歆勴枆 靸來櫓鞚� 鞐呺嵃鞚错姼頄堨姷雼堧嫟. 欤茧牓 頉勲炒氍检鞚� blarcamesine鞚� AAIC 2025鞐愳劀 氚滍憸霅� 氚旍檧 臧欖澊 瓴届 鞎岇笭頃橃澊毹� 頇橃瀽霌れ棎瓴� 4雲� 霃欖晥 歆�靻嶌爜鞚� 鞛勳儊鞝� 鞚挫爯鞚� 氤挫榾鞀惦媹雼�.
鞛 鞖旍暯鞙茧電� 2025雲� 6鞗� 30鞚� 旮办 順勱笀 氤挫湢鞎� $101.2M鞙茧 3雲� 鞚挫儊 鞖挫榿 鞛愱笀鞚� 頇曤炒霅橃柎 鞛堧嫟電� 鞝愳澊 韽暔霅╇媹雼�. 3攵勱赴 靾滌啇鞁れ潃 $13.2惭($0.16/欤�)鞙茧, 2024雲� Q3鞚� $12.2M($0.14/欤�)鞐� 牍勴暣 歃濌皜頄堨姷雼堧嫟. 鞐瓣惮臧滊皽牍勲姅 鞝勲厔 霃欔赴 雽�牍� $11.8M鞐愳劀 $10.0M鞙茧 臧愳唽頄堨溂雮�, G&A 牍勳毄鞚� $2.8M鞐愳劀 $4.5M鞙茧 歃濌皜頄堨姷雼堧嫟.
Anavex Life Sciences (NASDAQ:AVXL) a publi茅 ses r茅sultats financiers du troisi猫me trimestre de l'exercice 2025 et a fourni des informations sur ses avanc茅es cliniques. Son principal candidat-m茅dicament, blarcamesine, a d茅montr茅 des b茅n茅fices cliniques durables chez des patients atteints d'Alzheimer au stade pr茅coce sur une p茅riode de 4 ans, pr茅sent茅s lors de l'AAIC 2025.
Parmi les points financiers, on rel猫ve une tr茅sorerie de $101.2 millions au 30 juin 2025, assurant plus de 3 ans d'autonomie. La perte nette du troisi猫me trimestre s'茅l猫ve 脿 $13.2 millions ($0.16 par action), contre $12.2 millions ($0.14 par action) au T3 2024. Les d茅penses R&D ont diminu茅 脿 $10.0 millions contre $11.8 millions en glissement annuel, tandis que les frais G&A ont augment茅 脿 $4.5 millions contre $2.8 millions.
Anavex Life Sciences (NASDAQ:AVXL) ver枚ffentlichte seine Finanzergebnisse f眉r das dritte Quartal des Gesch盲ftsjahres 2025 und gab Updates zu seinen klinischen Entwicklungen. Der f眉hrende Wirkstoffkandidat, blarcamesine, zeigte laut Pr盲sentation auf der AAIC 2025 眉ber einen Zeitraum von vier Jahren anhaltende klinische Vorteile f眉r Patienten mit Fr眉hstadium-Alzheimer.
Zu den finanziellen Eckdaten geh枚rt eine Barmittelposition von $101.2 Millionen zum 30. Juni 2025, was mehr als 3 Jahre Laufzeit erm枚glicht. Der Quartalsverlust belief sich auf $13.2 Millionen ($0.16 je Aktie), gegen眉ber $12.2 Millionen ($0.14 je Aktie) im Q3 2024. Die F&E-Ausgaben sanken auf $10.0 Millionen von $11.8 Millionen im Jahresvergleich, w盲hrend die G&A-Kosten auf $4.5 Millionen von $2.8 Millionen anstiegen.
- Strong cash position of $101.2M providing over 3 years of runway
- Blarcamesine showed continued clinical benefits in Alzheimer's patients for up to 4 years
- Reduced R&D expenses by 15.3% year-over-year to $10.0M
- Oral administration of blarcamesine offers potential advantage over injectable alternatives
- Net loss increased to $13.2M from $12.2M year-over-year
- G&A expenses rose 60.7% to $4.5M compared to previous year
- Cash position decreased from $132.2M to $101.2M since September 2024
Insights
Anavex's Q3 shows steady clinical progress for blarcamesine in Alzheimer's, but wider losses and continuing cash burn require monitoring.
Anavex's fiscal Q3 2025 results paint a picture of continued clinical advancement amid growing financial pressures. The company's cash position has declined to
The company's net loss widened to
The clinical narrative centers on blarcamesine, their oral small molecule targeting early Alzheimer's disease. The 4-year extension data presented at AAIC 2025 demonstrated continued benefits measured by standard cognitive and functional assessments (ADAS-Cog13 and ADCS-ADL). Additionally, the company highlighted how their compound works upstream by restoring impaired autophagy, potentially addressing the disease before amyloid-beta and tau accumulation.
Importantly, a European stakeholder survey emphasized market preference for oral therapies like blarcamesine over injectable monoclonal antibodies, suggesting potential commercial advantages if approved. Oral administration could facilitate broader market penetration by reducing monitoring requirements and simplifying administration compared to current antibody treatments.
Blarcamesine shows promising long-term cognitive benefits in Alzheimer's with potential advantages as an oral therapy targeting autophagy mechanisms.
Anavex's blarcamesine data presented at AAIC 2025 represents a potentially significant development in the Alzheimer's treatment landscape. The compound demonstrates two particularly notable characteristics: its oral administration route and its upstream mechanism targeting autophagy.
The 4-year extension data showing continued clinical benefits on both cognitive function (ADAS-Cog13) and activities of daily living (ADCS-ADL) suggests durability of effect鈥攁 critical factor in Alzheimer's therapeutics where disease progression typically continues despite intervention. While specific numerical data wasn't provided in the release, the description of "clinically meaningful benefit" indicates the changes likely meet thresholds considered relevant for patients' quality of life.
Mechanistically, blarcamesine's focus on restoring impaired autophagy positions it differently from most approved Alzheimer's therapies. Autophagy鈥攖he cellular process that clears damaged proteins and organelles鈥攂ecomes dysfunctional early in Alzheimer's pathogenesis. By targeting this upstream process before amyloid-beta and tau accumulation, blarcamesine potentially addresses the disease cascade earlier than antibody therapies focused on clearing already-formed plaques and tangles.
The EU stakeholder survey highlighting preferences for oral therapies reflects practical clinical considerations. Current monoclonal antibody treatments require infusion infrastructure, monitoring for ARIA (amyloid-related imaging abnormalities), and specialized administration protocols. An effective oral therapy would significantly reduce these barriers, potentially expanding treatment to broader patient populations, particularly in settings with limited healthcare infrastructure. This modality difference could be crucial for real-world effectiveness even if efficacy in controlled trials were comparable.
Company to host a today at 8:30 a.m. Eastern Time
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (鈥淎navex鈥� or the 鈥淐ompany鈥�) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its third quarter of fiscal 2025.
鈥淥ur development of non-invasive, targeted upstream compounds continues to advance, particularly in the context of Alzheimer鈥檚 disease,鈥� said Christopher U. Missling, PhD, President and CEO of Anavex. 鈥淐linical feedback highlights the importance of orally administered therapies that are both accessible and effective. At AAIC 2025, we presented open-label extension data for blarcamesine, which demonstrated continued clinically meaningful benefit in early-stage Alzheimer鈥檚 patients鈥攆urther validating its therapeutic potential.鈥�
Recent Highlights:
- On July 31, 2025, Anavex announced the latest findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer鈥檚 disease. The data were presented by Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board at the 2025 Alzheimer's Association International Conference (AAIC). Blarcamesine-treated patients continue to accrue benefit through up to 4 years, as measured by the prespecified clinical endpoints ADAS-Cog13 and ADCS-ADL, respectively. Further presentations at the AAIC 2025 Conference featured prespecified Precision Medicine Phase IIb/III 48-week ANAVEX庐2-73-AD-004 double-blind (DB) clinical trial data on blarcamesine, confirming the upstream mechanism of blarcamesine, restoring impaired autophagy as an early event, preceding amyloid-beta and tau.
- July 27-31, 2025, Anavex was honored to be a part of the program at the 2025 Alzheimer鈥檚 Association International Conference (AAIC) in Toronto. The sharing of knowledge at these central events is important to help advance dementia science to better support the millions of individuals, families, and communities impacted by Alzheimer鈥檚 disease.
- In June 2025, a survey of Alzheimer鈥檚 Disease stakeholders from European Union (EU) Member States on 鈥楥urrent Unmet Needs in Alzheimer Care鈥� was conducted. There is a clear acknowledgment that oral therapies would 鈥榝acilitate things鈥� for many countries and be 鈥榤uch more accessible鈥� for the respective healthcare systems, potentially requiring less extensive monitoring and complex administration compared to injectable monoclonal antibodies. This modality difference is seen as a key factor in potential broader market penetration.
Financial Highlights:
- Cash and cash equivalents of
$101.2 million at June 30, 2025 compared to$132.2 million at year ended September 30, 2024. The Company anticipates at current adjusted cash utilization rates and ranges, an approximate cash runway of more than 3 years. - Research and development expenses for the quarter of
$10.0 million compared to$11.8 million for the comparable quarter of fiscal 2024. - General and administrative expenses for the quarter of
$4.5 million compared to$2.8 million for the comparable quarter of fiscal 2024. - An increase in non-cash compensation charges, was offset by a decrease in overall cash operating expenses, as compared to the same quarter of fiscal 2024.
- Net loss for the quarter of
$13.2 million , or$0.16 per share, compared to a net loss of$12.2 million , or$0.14 per share for the comparable quarter of fiscal 2024.
The financial information for the quarter ended June 30, 2025, should be read in conjunction with the Company鈥檚 consolidated financial statements, which will appear on EDGAR, www.sec.gov and will be available on the Anavex website at .
Webcast / Conference Call Information:
The live of the conference call will be available on Anavex鈥檚 website at .
The conference call can be also accessed by dialing 1 929 205 6099 for participants in the U.S. using the Meeting ID# 856 5033 5285 and reference passcode 014 352. A replay of the conference call will also be available on Anavex鈥檚 website for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX庐2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX庐2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX庐2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX庐2-73 for the treatment of Parkinson's disease. We believe that ANAVEX庐3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX庐3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at . You can also connect with the Company on , , and .
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company鈥檚 most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
| Anavex Life Sciences Corp. | |||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | |||||||
| (in thousands, except share and per share amounts) (Unaudited) | |||||||
| 听 | |||||||
| 听 | Three months ended June 30, | ||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Operating Expenses | 听 | 听 | |||||
| General and administrative | $ | 4,500 | 听 | 听 | $ | 2,792 | 听 |
| Research and development | 听 | 9,959 | 听 | 听 | 听 | 11,811 | 听 |
| Total operating expenses | 听 | 14,459 | 听 | 听 | 听 | 14,603 | 听 |
| Operating loss | 听 | (14,459 | ) | 听 | 听 | (14,603 | ) |
| 听 | 听 | 听 | |||||
| Other income | 听 | 听 | |||||
| Grant income | 听 | 25 | 听 | 听 | 听 | - | 听 |
| Research and development incentive income | 听 | 127 | 听 | 听 | 听 | 526 | 听 |
| Interest income, net | 听 | 1,075 | 听 | 听 | 听 | 1,796 | 听 |
| Foreign exchange gain | 听 | (11 | ) | 听 | 听 | 67 | 听 |
| Total other income, net | 听 | 1,216 | 听 | 听 | 听 | 2,389 | 听 |
| Net loss and comprehensive loss | $ | (13,243 | ) | 听 | $ | (12,214 | ) |
| 听 | 听 | 听 | |||||
| Net loss per share | 听 | 听 | |||||
| Basic and diluted | $ | (0.16 | ) | 听 | $ | (0.14 | ) |
| 听 | 听 | 听 | |||||
| Weighted average number of shares outstanding | 听 | ||||||
| Basic and diluted | 听 | 听听听听听听听 85,380,587 | 听 | 听 | 听 | 听听听听听听听听听听 84,535,328 | 听 |
| 听 | |||||||
| Anavex Life Sciences Corp. | |||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | |||||||
| (in thousands, except share and per share amounts) (Unaudited) | |||||||
| 听 | |||||||
| 听 | Nine months ended June 30, | ||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Operating Expenses | 听 | 听 | |||||
| General and administrative | $ | 听听听听听听听听听听听听听听听听10,266 | 听 | 听 | $ | 听听听听听听听听听听听听听听听听8,382 | 听 |
| Research and development | 听 | 听听听听听听听听听听听听听听 30,298 | 听 | 听 | 听 | 听听听听听听听听听听听听听听听听 30,224 | 听 |
| Total operating expenses | 听 | 听听听听听听听听听听听听听听 40,564 | 听 | 听 | 听 | 听听听听听听听听听听听听听听听听 38,606 | 听 |
| Operating loss | 听 | (40,564 | ) | 听 | 听 | (38,606 | ) |
| 听 | 听 | 听 | |||||
| Other income (expense) | 听 | 听 | |||||
| Grant income | 听 | 听听听听听听听听听听听听听听听听听听听听听 37 | 听 | 听 | 听 | - | 听 |
| Research and development incentive income | 听 | 听听听听听听听听听听听听听听听听听听听 635 | 听 | 听 | 听 | 听听听听听听听听听听听听听听听听听听 1,591 | 听 |
| Interest income, net | 听 | 听听听听听听听听听听听听听听听听 3,679 | 听 | 听 | 听 | 听听听听听听听听听听听听听听听听听听 5,561 | 听 |
| Foreign exchange gain (loss) | 听 | 听听听听听听听听听听听听听听听听听 (337 | ) | 听 | 听 | 听听听听听听听听听听听听听听听听听听听听听 72 | 听 |
| Total other income, net | 听 | 听听听听听听听听听听听听听听听听 4,014 | 听 | 听 | 听 | 听听听听听听听听听听听听听听听听听听 7,224 | 听 |
| Net loss and comprehensive loss | $ | 听听听听听听听听听听听听听听听听(36,550 | ) | 听 | $ | 听听听听听听听听听听听听听听听听(31,385 | ) |
| 听 | 听 | 听 | |||||
| Net loss per share | 听 | 听 | |||||
| Basic and diluted | $ | 听听听听听听听听听听听听听听听听(0.43 | ) | 听 | $ | 听听听听听听听听听听听听听听听听(0.38 | ) |
| 听 | 听 | 听 | |||||
| Weighted average number of shares outstanding | 听 | ||||||
| Basic and diluted | 听 | 85,085,795 | 听 | 听 | 听 | 83,022,330 | 听 |
| 听 | ||||||
| Anavex Life Sciences Corp. | ||||||
| Condensed Consolidated Balance Sheets | ||||||
| (in thousands, except share and per share amounts) | ||||||
| 听 | 听 | |||||
| 听 | June 30, | September 30, | ||||
| 听 | 听 | 2025 | 听 | 听 | 2024 | 听 |
| Assets | 听 | 听 | ||||
| Current | 听 | 听 | ||||
| Cash and cash equivalents | $ | 101,164 | 听 | $ | 132,187 | 听 |
| Incentive and tax receivables | 听 | 听听听听听听听听听听听听听听听听听听听听听听 听听听 820 | 听 | 听 | 听听听听听听听听听听听听听听听听听听 2,449 | 听 |
| Prepaid expenses and other current assets | 听 | 听听听听听听听听听听听听听听听听听听听听听听 听听听 448 | 听 | 听 | 听听听听听听听听听听听听听听听听听听听听听 931 | 听 |
| Total Assets | $ | 102,432 | 听 | $ | 135,567 | 听 |
| 听 | 听 | 听 | ||||
| Liabilities and stockholders' equity | 听 | 听 | ||||
| Current Liabilities | 听 | 听 | ||||
| Accounts payable | $ | 6,740 | 听 | $ | 9,627 | 听 |
| Accrued liabilities | 听 | 听听听听听听听听听听听听听听听听听听听听 3,929 | 听 | 听 | 听听听听听听听听听听听听听听听听听听 4,835 | 听 |
| Deferred grant income | 听 | 听听听听听听听听听听听听听听听听听听听听听听听听听 805 | 听 | 听 | 听听听听听听听听听听听听听听听听听听听听听 842 | 听 |
| Total Liabilities | 听 | 听听听听听听听听听听听听听听听听听听听听 11,474 | 听 | 听 | 听听听听听听听听听听听听听听听听 15,304 | 听 |
| Capital Stock | 听 | 听听听听听听听听听听听听听听听听听听听听听听听听听 85 | 听 | 听 | 85 | 听 |
| Additional paid-in capital | 听 | 听听听听听听听听听听听听听听听听听听 463,494 | 听 | 听 | 听听听听听听听听听听听听听听 456,249 | 听 |
| Accumulated deficit | 听 | (372,621 | ) | 听 | (336,071 | ) |
| Total Stockholders' Equity | 听 | 听听听听听听听听听听听听听听听听听听 听听 90,958 | 听 | 听 | 听听听听听听听听听听听听听听 120,263 | 听 |
| Total Liabilities and Stockholders' Equity | $ | 102,432 | 听 | $ | 135,567 | 听 |
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email:
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email:
FAQ
What were Anavex's (AVXL) key financial results for Q3 2025?
How long is Anavex's (AVXL) cash runway as of Q3 2025?
What were the latest clinical results for Anavex's blarcamesine in Alzheimer's disease?
How does Anavex's Q3 2025 net loss compare to the previous year?
What advantage does blarcamesine offer over other Alzheimer's treatments?
